Hims & Hers Health Soars over 8% on FDA Peptide Deregulation and Novo Nordisk Partnership
Stock Track04-20 22:36
Hims & Hers Health stock soared 8.43% on Monday, extending a multi-day rally.
The surge is driven by significant regulatory and commercial catalysts. The U.S. FDA plans to remove 12 peptides from its restricted list and will convene an advisory panel to assess their production by compounding pharmacies, a move that could substantially expand Hims's market in metabolic health and anti-aging treatments. Concurrently, the company entered a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs directly on its platform, adding a major new revenue stream.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
